Novartis ADR Representing 1 Ord Shs (NVS)
$88.29
0.17 (0.20%)
NVS Stock Quote Delayed 30 Minutes
Previous Close
$88.12
Market Cap
205.79B
PE Ratio
25.89
EPS
3.41
Volume (Avg. Vol.)
34,546
Day's Range
88.10 - 88.24
52-Week Range
69.18 - 99.84
Dividend & Yield
2.98 (3.37%)
NVS Stock Predictions, Articles, and Novartis ADR Representing 1 Ord Shs News
This Stock Points to the Massive China Biotech Trend
There is ridiculously big upside potential for Chinese biotech stocks in the next decade. The spread of the pandemic has only strengthened the case.
Stock Market Today: Merger Monday; Tesla’s Cybertruck Pre-Orders
Tesla hit 200,000 pre-orders and there was a bevy of M&A to report. Here's what happened in the stock market today.
The Medicines Company News: MDCO Stock Rockets 22% on Novartis Deal
The Medicines Company (MDCO) news for Monday about a $9.70 billion deal with Novartis (NVS) has MDCO stock heading higher.
3 Biotech Stocks That Show The Good, The Bad and the Ugly Side of This Sector
When rumors start buzzing that the government may be about to intervene, then biotech stocks often get slammed...some fairly, and some not (as we’ll see).
10 Smart Dividend Stocks for the Rest of the Year
Ford, Verizon and AbbVie are just a trio of the top dividend stocks to buy for the remainder of 2019, particularly if the broad market hits turbulence.
New Sanofi CEO 2019: 8 Things to Know About Paul Hudson
There's a new Sanofi CEO preparing to join the company with current CEO Olivier Brandicourt retiring at the end of August.
Continued Smart M&A Moves Will Help Canopy Stock Break Out
Of course, the medical opportunity is massive, but Tilray competitor, Canopy Growth (NYSE:CGC), has been aggressively pursuing a multi-pronged approach that inherently diversifies the future revenue streams. CGC’s vision for THC as an ingredient in an array of consumer products separates them from an increasingly crowded industry.
4 Top Stock Trades for Tuesday: ROKU, ADSK, SPLK, NVS
Roku, Autodesk, Splunk and Novartis are our top stock trades on Friday. Going into the long weekend, see why we picked them for next week.
How and Why Tilray Stock Is a Buy Here
Following a long, steep correction and on the heels of earnings, there’s less to fear in stepping into a contrarian position in Tilray stock.
Don’t Let the Great Q1 Numbers Fool You into Buying Tilray Stock
After a revenue beat Tilray Inc (NASDAQ:TLRY) saw its stock jump 5 percent for the day. However, that optimism has faded rather quickly, and TLRY stock has not been able to capitalize on that momentum.
Here’s the Real Problem with Altria Overpaying for CRON Stock
Altria Group Inc (NYSE:MO) was the latest in a frenzied string of M&A and partnerships in the cannabis sector. Marijuana stocks have been the target of billion-dollar investments, and the $102 billion market cap company and owner of veteran cigarette brands Marlboro, Parliament, and Virginia Slims, last month that it was investing approximately $1.8 billion in Canadian-based Cronos Group Inc (NASDAQ:CRON), which is listed both on the TSX as well as the NASDAQ.
3 Big Stock Charts for Wednesday: Incyte, FMC and LyondellBasell
The stock charts of INCY, LYB and FMC are going to start this week's hump-day at a precipice. Here are the numbers to know.
Novartis News: NVS Stock Sinks Following Alcon Spin-Off
Novartis news about the company's spin-off of Alcon into its own publicly-traded company has NVS stock falling hard on Tuesday.
The Roche Merger Will Do Wonders for Spark Stock
As Spark Therapeutics gets acquired, existing shareholders, and Roche investors, will need to eveluate the merits of the deal.
Navellier Ratings
Powered by Portfolio GraderTotal Grade
C
